Fennec Pharmaceuticals (TSX:FRX) Pre-Tax Income : C$-21.64 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Fennec Pharmaceuticals's pretax income for the three months ended in Dec. 2023 was C$-3.60 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was C$-21.64 Mil. Fennec Pharmaceuticals's pretax margin was -27.55%.

During the past 13 years, Fennec Pharmaceuticals's highest Pretax Margin was -75.50%. The lowest was -10640.37%. And the median was -1545.08%.

Fennec Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Fennec Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Pre-Tax Income Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-16.82

-23.20

-22.20

-32.22

-21.53

Fennec Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-9.32	-8.28	-7.23	-2.53	-3.60

Competitive Comparison of Fennec Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Fennec Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Pre-Tax Income falls into.

Fennec Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Fennec Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-17.519	+	-0.046	+	-4.553	+	0.592	+	0
	=	-21.53

Fennec Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.533	+	0.008	+	-1.228	+	0.154	+	0.0010000000000003
	=	-3.60

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.64 Mil.

Fennec Pharmaceuticals (TSX:FRX) Pre-Tax Income Explanation

Fennec Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-3.598	/	13.06
	=	-27.55%

During the past 13 years, Fennec Pharmaceuticals's highest Pretax Margin was -75.50%. The lowest was -10640.37%. And the median was -1545.08%.

Fennec Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (TSX:FRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.